Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMAYWXD)

Drug Name
VA-111913 Drug Info
Synonyms VA-111913 TS; VA-913; VT-913; V1a antagonists (dysmenorrhea), Vantia; Vasopressin 1a antagonists (dysmenorrhea), Vantia/Ferring
Indication
Disease Entry ICD 11 Status REF
Dysmenorrhea GA34.3 Phase 2 [1]
Cross-matching ID
PubChem CID
135564707
CAS Number
CAS 877856-17-2
TTD Drug ID
DMAYWXD

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Vasopressin V1a receptor (V1AR) TT4TFGN V1AR_HUMAN Antagonist [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Vasopressin V1a receptor (V1AR) DTT AVPR1A 4.689 3.609 4.591 3.878
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Dysmenorrhea
ICD Disease Classification GA34.3
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Vasopressin V1a receptor (V1AR) DTT AVPR1A 8.89E-04 -0.12 -0.34
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT00963053) VA111913 Dysmenorrhoea Efficacy and Safety Proof of Concept. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of Avarx.